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Gene regulationAF9 is known to interact with multiple proteins including activators and repressors of transcription.
Our data indicate that other AF9 binding proteins compete with the histone methyltransferase
DOT1L for AF9 binding thus diminishing its ability to methylate lysine 79 of histone 3. Speciﬁcally,
we show that AF9 is part of a protein multimer containing members of Polycomb group (PcG) PRC1
complex, CBX8, RING1B, and BMI1. Interaction with CBX8 precludes AF9–DOT1L binding. Knock-
down of CBX8 with short-hairpin RNA (shRNA) leads to decreased expression of the AF9 target gene
ENaCa. In contrast, CBX8 overexpression results in increased ENaCamRNA levels and this effect can
be partially overcome by co-overexpression of AF9.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
AF9/MLLT3, located on chromosome band 9p22, was ﬁrst identi-
ﬁed as a fusion partner of theMixed Lineage Leukemia (MLL) gene in
acute lymphoid and myeloid leukemias [1–3]. The function of AF9
has not been completely characterized but a homozygous null
mutation of Af9 in mice is known to cause death in the perinatal
period. These mice have axial skeleton defects suggesting a role
for Af9 in normal embryogenesis through interplay with HOX gene
function [4]. Apart from its role in development, recent studies
indicate that AF9 is an important factor for the expression of genes
that regulate normal hematopoiesis including GATA1. It has been
shown that AF9 is highly expressed in hematopoietic stem cells
and short-hairpin RNA (shRNA)-mediated knock down of AF9 in
cord blood (CB) CD34+ CD38 cells results in complete abrogation
of erythrocyte colony formation [5]. Moreover, in hematopoieticprecursor cells, expression of a chimeric protein comprising of
the C-terminus of AF9 fused to the N-terminus of MLL leads to leu-
kemic transformation [6,7]. Thus AF9 has role in both normal as
well as neoplastic blood cell development.
Earlier studies have also shown that Af9 is important in renal
salt homeostasis, brain development and HIV gene transcription
by regulating the expression of Enaca and Tbr1 genes and by indi-
rect recruitment of HIV Tat protein, respectively [8–11]. Perhaps
the best characterized target of Af9 is epithelial sodium channel
gene a (Enaca). It has been shown in murine renal collecting ducts
that Af9 together with the methyltransferase Dot1l result in his-
tone H3 lysine 79 (H3K79) hypermethylation at the Enaca pro-
moter region which then contributes to a repressed state of gene
expression [8]. Similarly, Af9 in conjunction with Dot1l negatively
regulates the expression of the Tbr1 gene in the subventricular
zone of mouse forebrain by governing the status of H3K79 methyl-
ation at its transcription start site [9]. This repressive activity of the
H3K79 methylation mark by Dot1l is in contrast to canonical
H3K79 methylation that is predominantly associated with actively
transcribed genes [12].
In addition to DOT1L, AF9 has also been found to directly bind at
least three other functionally and structurally unrelated proteins
via its carboxy-terminal domain (CTD) [13]. AF9 has been shown
to exist in a large multi-protein complex containing AF4, another
commonly encountered MLL fusion partner, and positive transcrip-
tion elongation factor b (P-TEFb) comprised of cyclin T1 and CDK9
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phosphorylation of Ser2 of the CTD of the large subunit of RNA
Pol II which promotes productive transcriptional elongation of ini-
tiated mRNA transcripts [15,16]. It is through this process that AF9
is required for optimal transcription of HIV genes in conjunction
with Tat. In this context, DOT1L is not a part of the AF9–AF4–P-
TEFb complex [13]. AF9 is also known to directly interact with
two repressors of transcription, the Polycomb protein CBX8, and
the BCL6 co-repressor BCoR [17,19]. Here we investigate the
AF9–CBX8 protein interaction. CBX8 is a component of the Poly-
comb-group (PcG) repressive complex 1 (PRC1). We ﬁnd that an
AF9–CBX8 complex also contains other PRC1 proteins. The AF9–
DOT1L complex is distinct from the AF9–PRC1 complex. Experi-
mentally manipulating levels of CBX8 has a direct effect on the
abundance of AF9–DOT1L complexes and affects the expression
of an AF9–DOT1L regulated gene. By way of these interactions
overexpression of CBX8, typically a repressor of gene expression,
leads to increased expression of the ENaCa gene.
2. Materials and methods
2.1. Cell culture and transfection
The MV4-11 human leukemia cell line (ATCC) expressing AF9
was maintained in RPMI 1640 medium with 10% fetal bovine ser-
um, 1.1% Penicillin–Streptomycin (Pen/Strep) and 2.2% Glutamine.
HEK293T cells (Clontech) were maintained in DMEM supple-
mented with 10% fetal bovine serum and 1.1% Pen/Strep. Cells were
incubated at 37o C in room air plus 5% CO2. For transient transfec-
tions of DNA expression vectors and shRNA, Lipofectamine2000™
reagent (Life Technologies) was used according to the manufac-
turer’s protocol. Cells were harvested 48 h after transfection.
GFP–RI3A–(AF4), GFP–DOT1L, pCMV3XFLAG–AF9, and HA–BCoR
expression vectors were described previously [14,19]. Myc–DDK–
CBX8, Myc–DDK–BMI1 expression vectors and CBX8 shRNA were
purchased from OriGene.
2.2. Immunoprecipitation
HEK293T cells transiently transfected with the designated gene
expression vectors and/or shRNA were lysed in 1 ml lysis buffer
(30 mM Tris pH 7.4, 150 mM NaCl, 0.5% Triton-X 100 (v/v), 1 pro-
tease inhibitor cocktail and 1 mM DTT). 48 h after transfection
cleared cell lysates were incubated with anti-FLAG antibody (Sig-
ma # F1804) or isotype control antibody. The immunoprecipitate
was separated by SDS 4–12% PAGE followed by Western blotting
to detect CBX8 (Bethyl # A300-882A), RING1A (Cell Signaling #
2820), RING1B (Santa Cruz # sc-101109), and BMI1 (Cell Signaling
# 5856). To examine the interaction status between BMI1 and
other AF9 interacting proteins, HEK293T cells co-expressing
MYC–DDK–BMI1, GFP–AF4, GFP–DOT1L, or HA–BCoR were immu-
noprecipitated using either anti-Myc (Upstate # 06-549) or anti-
DDK (Origene # TA50011). The immunoprecipitate was separated
by SDS 4–12% PAGE followed by Western blotting to detect GFP
(Life Technologies # A11122) or HA (Sigma # H3663) epitope tags
that were fused to AF4, DOT1L and BCoR.
2.3. Size exclusion chromatography
1.0  109 MV4-11 cells were lysed by resuspension in 1 ml of
lysis buffer (20 mM HEPES pH 7.2, 150 mM KCl, 2 mM EDTA,
1 mM DTT, 1 protease inhibitor cocktail, 1 PMSF) and passaged
through a dounce homogenizer. 250 ll (approximately 1.5 mg
total protein) of cleared cell lysate was then applied to a Superose
6 10/300 GL column (GE Healthcare) with a fractionation range of
5KDa–5MDa. Subsequently, 96250 ll fractions were collectedusing Fast Pressure Liquid Chromatography (FPLC) at a ﬂow rate
of 0.35 ml/min and maximum pressure of 1.5 MPa. The fractions
were then analyzed by SDS 4–12%-PAGE followed by Western
blotting for AF9 (Novus Biologicals # NB100-1566), RING1B (Santa
Cruz # sc-101109) and CBX8 (Bethyl # A300-882A).
2.4. Quantitative reverse transcriptase polymerase chain reaction
(qRT-PCR)
HEK293T cells were transiently transfected with the designated
gene expression vectors and/or shRNA. Cells were harvested after
72 h and RNA was extracted using RNeasy kit (Qiagen). 2 lg RNA
was then converted into cDNA using SuperScript III First Strand
Synthesis Super Mix kit (Life Technologies). SYBR Green Supermix
with ROX (BioRad) was used to perform quantitative PCR using 1:5
diluted cDNA and primers for the human ENaCa gene (F: ATGACTT-
CATTCCCCTGCTG, R: CATCACTGCCATTCTTGGTG) and GAPDH
(primers provided in the EZ-Magna ChIPTM A/G protocol)
[Milipore]).
2.5. Chromatin immunoprecipitation (ChIP)
HEK293T cells were transiently transfected with the indicated
expression vectors. 48 h later, cells were ﬁxed with 1% formalde-
hyde; ChIP was performed using the EZ-Magna ChIP™ A/G protocol
(Milipore). The lysate was precipitated overnight at 4o C using anti-
H3 (abcam # ab12079), anti-tri-methylated H3K79 (abcam #
ab2621), anti-Myc and isotype control antibodies at concentrations
of 3 lg/ml. The eluted DNA was then subjected to quantitative PCR
using two different sets of primers for the ENaCa promoter regions
(P1a F: ACCTCGAGCTGTGTCCTGAT, R: GCCCTGCTCACCTTTAATTG;
P1b F: GTACTGGACCTGAGAAGGCG, R: CTTCTCCTTGTGTTGCCCTC).
3. Results
3.1. AF9 associates with PRC1 complex proteins
AF9 has been shown previously to interact directly with CBX8
and indirectly with RING1B through RING1B–CBX8 binding [17].
We examined whether AF9 interacts with other PRC1 components,
including RING1A, BMI1, and HPH1. HEK293T cells expressing
FLAG–AF9 efﬁciently precipitated endogenous CBX8, RING1A,
RING1B and BMI1 using anti-FLAG antibody (Fig. 1A). In contrast,
we did not detect HPH1 in the immunoprecipitate (data not
shown). We next assessed whether the reciprocal is true, namely
that immunoprecipitation of BMI1 can also capture AF9. We have
previously demonstrated that (1) BMI1 binds RING1B through
the RING ﬁnger domains of the two proteins. Furthermore, (2)
CBX8 directly binds RINGB through its C-terminal C-box. Finally,
(3) CBX8 binds the C-terminal domain of AF9 [17,18]. We predicted
that these sequential protein interactions would link AF9 to BMI1.
As shown in Fig. 1B, HEK293T cells expressing FLAG–AF9 contain
AF9 in anti-BMI1 immunoprecipitates. These ﬁndings support a
model in which a fraction of the total cellular AF9 exists within
complexes containing at least four PcG proteins of the PRC1
complex.
3.2. AF9 and CBX8 are found within a 300–400 kDa complex
Afﬁnity puriﬁcation of AF9 and its homolog ENL has shown that
they associate, directly or indirectly, with a large number of pro-
teins including activators and repressors of transcription
[13,20,21]. However, it has not been fully determined to what ex-
tent AF9 forms mega-Dalton complexes collectively comprised of
most of these proteins or whether it forms smaller distinct com-
plexes each of which contain a speciﬁc subset of AF9 interacting
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Fig. 1. AF9 interacts with components of the PRC1 complex. (A) HEK293T cells were transiently transfected with FLAG–AF9. Whole cell lysate was then immunoprecipitated
with an anti-FLAG antibody. The immunoprecipitate was then analyzed byWestern blot for PRC1 proteins. (B) HEK293T cells were transiently transfected with FLAG–AF9 and
whole cell lysate was immunoprecipitated with an anti-BMI1 antibody. The immunoprecipitate was then analyzed byWestern blot to detect AF9 with an anti-FLAG antibody.
The ﬁgures are representative of three independent experiments.
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subsets of AF9–CBX8 interacting proteins by size exclusion chro-
matography. Whole cell lysate was prepared from the MV4-11
leukemia cell line that is known to express AF9. The lysate was
then applied to a Superose 6 10/300GL column and fractions were
collected using FPLC. The individual fractions were then subjected
to SDS–PAGE and probed for the presence of AF9 by Western blot.
As shown in Fig. 2, AF9 is present in higher molecular weightfractions ranging from 158–440 kDa. We then looked for the pres-
ence of other known AF9 interacting proteins focusing on members
of the Polycomb group (PcG) PRC1 complex, CBX8 and RING1B. As
shown, CBX8 is present in fractions 57 and 58, and RING1B is pres-
ent in fractions 58 and 59. These results suggest that PRC1 proteins
are found with AF9 as components of complexes restricted in mass
to 300–400 kDa and that PRC1 proteins do not promiscuously asso-
ciate with AF9.
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(C). The ﬁgures are representative of three independent experiments.
B. Malik, C.S. Hemenway / FEBS Letters 587 (2013) 3038–3044 30413.3. AF9–PRC1 complexes do not contain other known AF9 binding
partners
Our immunoprecipitation and gel ﬁltration experiments sug-
gest that AF9 is a component of several physically distinct com-
plexes. In addition to CBX8, it has been shown that AF9 directly
binds to AF4–P-TEFb, BCoR and DOT1L [8,15,19]. In order to deter-
mine whether AF9–PRC1 proteins exist as separate complexes that
exclude the other known AF9-binding proteins, we performed co-
immunoprecipitation experiments using HEK293T cells co-
expressing Myc–DDK–BMI1 in conjunction with GFP–AF4RI
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representative of three independent experiments.(Fig. 3A), GFP–DOT1L (Fig. 3B), HA–BCoR (Fig. 3C), or FLAG–AF9
(Fig. 3D). Since BMI1 efﬁciently precipitated FLAG–AF9 (Fig. 1B),
we wished to analyze whether other AF9 interacting proteins could
also be recovered with Myc–DDK–BMI1. As shown in Fig. 3A–C,
Myc–DDK–BMI1 was not able to immunoprecipitate GFP–AF4,
GFP–DOT1L or HA–BCoR. As a control to verify that proteins were
effectively immunoprecipitated in the process, blots were probed
with DDK (Fig. 3A and B) or Myc (Fig. 3C) antibodies to detect
the presence of BMI1. As an additional positive control, immuno-
precipitation of Myc–DDK–BMI1 revealed FLAG–AF9 (Fig. 3D).
Therefore, these ﬁndings suggest that AF9–PRC1 complexes do
not contain other proteins that directly bind AF9.
3.4. The association between AF9 and PRC1 proteins is mediated by
CBX8
Using a yeast two-hybrid assay, we found that AF9 and RING1B
can simultaneously bind CBX8 to form a ternary complex [17]. In
order to determine whether CBX8 is also required for the associa-
tion between AF9 and other PRC1 components, we knocked down
CBX8 using shRNA in HEK293T cells and determined the effect on
the interaction between AF9–PRC1 proteins. As shown in Fig. 4,
knocking down CBX8 impaired the ability to co-precipitate
FLAG–AF9 and RING1B as well as BMI1, without affecting the total
levels of BMI1, RING1B or FLAG–AF9. We conclude that CBX8 func-
tions, in part, as a scaffold to support the assembly of AF9–PRC1
complexes.
3.5. The association between AF9–CBX8 affects ENaCa gene expression
To examine the effect of AF9–CBX8 interactions on a known AF9
target gene, we performed qRT-PCR to measure the expression of
ENaCa. We ﬁrst knocked down CBX8 using shRNA in HEK293T cells
with scrambled shRNA used as a control. Knocking down CBX8 de-
creased ENaCa gene expression approximately 25% compared to
controls (Fig. 5A). Conversely, overexpression of CBX8 in HEK293T
cells resulted in an increase in ENaCa gene expression of approxi-
mately 80% (Fig. 5B). Moreover, this increase was partially blocked
by the co-expression of AF9. These ﬁndings suggest that although
CBX8 is a part of the repressive PRC1 complex, it acts as an activa-
tor of ENaCa gene expression by decreasing the relative abundance
of AF9–DOT1L complexes that repress ENaCa gene expression. To
test this directly, we expressed epitope-tagged AF9 and DOT1L inNG1a
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precipitation of DOT1L yields substantially less AF9 when CBX8
is over-expressed conﬁrming that CBX8 competes with DOT1L for
AF9 binding (Fig. 5C).
3.6. Increased expression of CBX8 impedes the recruitment of DOT1L to
the ENaCa promoter
We hypothesized that overexpression of CBX8 increases ENaCa
gene expression by reducing the recruitment of DOT1L to ENaCa
promoter regions. To test this hypothesis, we performed ChIP using
HEK293T cells transfected with Myc–DDK–CBX8. Antibodies
recognizing tri-methylated H3K79 were used to identify the
DOT1L-mediated chromatin mark. We used two primer sets for
promoter regions as shown in Fig. 6A. Overexpression of CBX8 re-
sulted in decreased H3K79 tri-methylation at both promoter re-
gions. This was accompanied by increased recruitment of CBX8
to these regions (Fig. 6B). These ﬁndings suggest that a shift in
the relative quantities of physically and functionally distinct AF9
complexes alters the regulation of AF9 target genes.4. Discussion
Here, we show that AF9 associates with components of the
PRC1, including CBX8, BMI1, RING1B and RING1A. More speciﬁ-
cally, we show that CBX8 is required for the interaction between
AF9 and other PRC1 components. Five different CBX proteins have
been identiﬁed in mammals- CBX2, CBX4, CBX6, CBX7, and CBX8.
The proteins share a homologous N-terminal chromodomain and
a C-terminal C-box [22]. The chromodomain mediates interactions
with methylated histone H3 and the different proteins recognize
different methylation marks [23]. The C-box promotes binding to
the Ring-ﬁnger proteins RING1A and RING1B which, in turn, medi-
ate monoubiquitination of histone H2A at lysine 119 [24]. Of the
ﬁve CBX proteins, only CBX8 is found in complexes containing
AF9 or its homolog ENL [13,20]. We earlier reported that the AF9
binding domain of CBX8 is not conserved among the CBX proteins
likely accounting for the speciﬁcity of the CBX8–AF9 interaction
[17].
While CBX8 is the only CBX protein that binds AF9, AF9 in turn
binds directly to at least three other proteins, AF4, DOT1L, and
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domain at the C-terminus of AF9 designated the AHD. The AHD it-
self is intrinsically disordered but adopts a unique structural
conformation for each of the four proteins to which it binds [25].
In this report, we provide evidence that shifts in the abundance
of different AF9 complexes directly affects AF9 target genes. Specif-
ically, we show that changes in the expression of CBX8 alter the
activity of another AF9-binding protein DOT1L whose function is
dependent on AF9 binding [8]. In human embryonic kidney cellsmethylation of H3K79 by DOT1L represses ENaCa gene expression
a known target of AF9–DOT1L. CBX8, by competing for AF9 bind-
ing, reduces H3K79 methylation at the ENaCa promoter and en-
hances expression of the gene. This leads to the seemingly
paradoxical ﬁnding that overexpression of a repressive PcG protein
actually up-regulates the expression of a gene. Our studies do not
address whether other PRC1 proteins are required for CBX8 to
modulate DOT1L activity, although overexpression of CBX8 alone
(and not other PRC1 proteins) is sufﬁcient for this effect. In the
3044 B. Malik, C.S. Hemenway / FEBS Letters 587 (2013) 3038–3044pathological setting of MLL–AF9 induced leukemia in which CBX8
is required, it has been shown that CBX8 functions independently
of other PRC1 proteins [26].
By way of dynamic changes with its four binding partners, AF9
serves to mediate the activities of protein complexes that function
in essential cellular processes ranging from transcription elonga-
tion to epigenetic regulation. Drug-like molecules that are able to
either promote or block the binding of speciﬁc AF9 interacting pro-
teins are therefore predicted to have important effects on disease
processes that subvert AF9.
Note added in proof
While this manuscript was under revision, Maethner et al.
reported on the interaction of PRC1 with MLL-ENL [27].
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